Processa Pharmaceuticals, Inc. (PCSA) is a Maryland-based clinical-stage pharmaceutical company dedicated to the development and commercialization of innovative therapeutics to improve the survival and quality of life for patients with high unmet medical needs. The company focuses on diseases that are not effectively treated with currently available therapy, filling the void and addressing significant unmet clinical needs.
Processa has assembled a respected group of experts in the drug development field, including regulatory affairs, clinical pharmacology, and pharmaceutical development. These experienced professionals, led by Dr. David Young, a former regulatory reviewer and former CEO of Promet Therapeutics, are steadfast in their commitment to advancing drugs from clinical development to commercialization.
The Company's lead drug candidate, PCS6422, is being developed to treat colorectal and breast cancer patients. Other drug candidates include PCS499, used for the treatment of Necrobiosis Lipoidica, and PCS12852, aimed at treating Gastrointestinal and Cardiovascular disorders.
Founded in 2015, Processa Pharmaceuticals, Inc.'s strategy is to identify and acquire assets with a known clinical history and redefine its development context and treatment paradigm based on more recent findings in disease area biology. By effectively conducting clinical trials, they aim to maximize the value of therapeutic assets for the benefit of patients and stakeholders.
Processa's approach sets it distinctively apart from other pharmaceutical companies. Their operations model is so designed that it allows for a rapid and cost-effective approach to drug development, which consequently leads to the possibility of achieving valuable milestones in a shorter timespan.
The company’s ethos is firmly rooted in a patient-centric approach. They are dedicated to bringing medicinal solutions to patients who either have no treatment options or are not satisfactorily treated by existing products. Their dedication to making a tangible difference in patients' lives is evident through their persistent research and innovative drug development methods.
The value of Processa Pharmaceuticals (PCSA) lies not only in its game-changing portfolio of drug candidates, but also in its unique model of drug development and its dedicated team of experts. Through its innovative and patient-focused approach, Processa promises to make significant strides in the field of clinical-stage pharmaceutical development, providing hope for patients with high unmet medical needs.